current Medicare Drug
HRSA weighs rebate paperwork for 340B drug discounts
HRSA is taking comments on a pilot that would shift some drug savings to a rebate system. Covered entities would have to send claims-level data to manufacturers, and the agency estimates nearly 4 million annual burden hours if the pilot moves ahead.
Health Resources and Services Administration wants feedback on a 340B rebate model pilot. The notice says manufacturers and covered entities would handle new reporting, with hospitals and other providers carrying most of the data work.
- Comments are due July 15, 2026.
- HRSA says the pilot would involve manufacturers and 340B covered entities.
- Covered entities would have to submit claims data to support rebates.
- The notice estimates about 3.97 million burden hours a year if the pilot is implemented.
Hospitals, health centers and other 340B covered entities could face a new layer of reporting if HRSA moves ahead with a rebate model pilot. The notice, issued by the Health Resources and Services Administration on June 15, 2026, says covered entities would need to send specific data to manufacturers so rebates could be calculated on eligible drug purchases.
The agency says the pilot would be limited to manufacturers with current Medicare Drug Price Negotiation Program agreements for the initial price applicability years 2026 and 2027. Comments are due July 15, 2026.
A paper trail built for rebates
The proposal centers on a revised 340B Rebate Model Pilot Program application, implementation and evaluation process. HRSA says it would collect manufacturer pilot plans, monthly purchase reports and data from covered entities that request rebates, all for monitoring the pilot and program integrity.
In plain terms, the change would shift part of the 340B discount process from the front end to the back end. Instead of getting the lower price up front, covered entities would need to document purchases and match them with rebate claims after the fact.
The burden lands on the claims line
HRSA’s own burden estimate shows where the weight falls. The notice says 11 manufacturers would each file a pilot plan and monthly purchase reports, while 15,249 covered entities would submit claims data through a third-party platform.
The agency also says the covered-entity data would be comparable to information many providers already keep through existing billing and vendor systems. Still, the notice acknowledges concerns about staffing, systems changes, reconciliation work and privacy when patient-level or claims-level information has to move between providers and manufacturers.
Why this matters for 340B savings
The 340B program lets eligible providers buy certain outpatient drugs at discounted prices, freeing up money that often helps support care for low-income and rural patients. A rebate model could change the timing and mechanics of those savings, even if the underlying ceiling price concept stays the same.
That is why the paperwork notice is more than a forms exercise. For providers that already run thin margins, the practical question is how much extra administration the rebate system would add, and whether the new data flow becomes another cost of staying in the program.